Zynerba Pharmaceuticals, Inc.

NasdaqCM:ZYNE Stock Report

Market Cap: US$65.6m

Zynerba Pharmaceuticals Valuation

Is ZYNE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ZYNE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ZYNE ($1.3) is trading below our estimate of fair value ($53.8)

Significantly Below Fair Value: ZYNE is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for ZYNE?

Other financial metrics that can be useful for relative valuation.

ZYNE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-0.8x
PEG Ration/a

Price to Book Ratio vs Peers

How does ZYNE's PB Ratio compare to its peers?

The above table shows the PB ratio for ZYNE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average2.4x
NTRB Nutriband
5xn/aUS$62.7m
CTXR Citius Pharmaceuticals
0.8x49.9%US$62.7m
MRMD MariMed
0.8xn/aUS$57.3m
LABP Landos Biopharma
3.1x-37.1%US$71.7m
ZYNE Zynerba Pharmaceuticals
2.3x67.2%US$65.6m

Price-To-Book vs Peers: ZYNE is good value based on its Price-To-Book Ratio (2.3x) compared to the peer average (16.4x).


Price to Earnings Ratio vs Industry

How does ZYNE's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a23.7%
n/an/an/a
No. of CompaniesPB048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a23.7%
n/an/an/a
No more companies

Price-To-Book vs Industry: ZYNE is expensive based on its Price-To-Book Ratio (2.3x) compared to the US Pharmaceuticals industry average (1.6x).


Price to Book Ratio vs Fair Ratio

What is ZYNE's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ZYNE PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ZYNE's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ZYNE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Nov ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Oct ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Sep ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Aug ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Jul ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Jun ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
May ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Apr ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Mar ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Feb ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Jan ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Dec ’24n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Nov ’24n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Oct ’24US$1.28
US$1.26
-1.6%
11.6%US$1.40US$1.11n/a2
Sep ’24US$1.32
US$1.26
-4.9%
11.6%US$1.40US$1.11n/a2
Aug ’24US$0.35
US$5.80
+1,533.8%
69.1%US$10.00US$0.40n/a3
Jul ’24US$0.33
US$5.80
+1,679.1%
69.1%US$10.00US$0.40n/a3
Jun ’24US$0.32
US$5.10
+1,479.9%
72.1%US$10.00US$0.40n/a4
May ’24US$0.36
US$5.38
+1,384.8%
74.2%US$11.00US$0.50n/a4
Apr ’24US$0.43
US$5.38
+1,150.0%
74.2%US$11.00US$0.50n/a4
Mar ’24US$0.46
US$5.44
+1,075.2%
71.9%US$11.00US$0.76n/a4
Feb ’24US$0.64
US$5.44
+751.3%
71.9%US$11.00US$0.76n/a4
Jan ’24US$0.53
US$5.44
+926.4%
71.9%US$11.00US$0.76n/a4
Dec ’23US$0.56
US$6.44
+1,050.0%
57.9%US$11.00US$0.76n/a4
Nov ’23US$0.73
US$6.50
+791.0%
56.0%US$11.00US$1.00n/a4

Analyst Forecast: Target price is lower than the current share price.


Discover undervalued companies